United Arab Emirates

Last Updated 4 March 2023.

8 Vaccines Approved for Use in United Arab Emirates

• National Vaccine and Serum Institute
  Recombinant SARS-CoV-2 Vaccine (CHO Cell)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  3 trials in 2 countries

  Approval Source: scmp.com

  Protein Subunit

• Moderna
  Spikevax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 88 countries

  70 trials in 24 countries

  Approval Source: reuters.com

  RNA

• Pfizer/BioNTech
  Comirnaty

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 149 countries

  100 trials in 31 countries

  Approval Source: reuters.com

  RNA

• Gamaleya
  Sputnik Light

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 26 countries

  7 trials in 3 countries

  Approval Source: tass.com

  Non Replicating Viral Vector

• Gamaleya
  Sputnik V

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 74 countries

  25 trials in 8 countries

  Approval Source: cnbc.com

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  Vaxzevria

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 149 countries

  73 trials in 34 countries

  Approval Source: u.ae

  Non Replicating Viral Vector

• Sinopharm (Beijing)
  Covilo

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 93 countries

  39 trials in 18 countries

  Approval Source: nature.com

  Inactivated

• Valneva
  VLA2001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 33 countries

  9 trials in 4 countries

  Approval Source: valneva.com

  Inactivated

10 Vaccines in Clinical Trials in United Arab Emirates

• Jiangsu Rec-Biotechnology Co Ltd
  ReCOV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  6 trials in 3 countries

  Protein Subunit

• National Vaccine and Serum Institute
  Recombinant SARS-CoV-2 Vaccine (CHO Cell)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  3 trials in 2 countries

  Protein Subunit

• Novavax
  Nuvaxovid

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 40 countries

  22 trials in 14 countries

  Protein Subunit

• Sinocelltech
  SCTV01C

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  12 trials in 2 countries

  Protein Subunit

• Gamaleya
  Sputnik V

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 74 countries

  25 trials in 8 countries

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  Vaxzevria

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 149 countries

  73 trials in 34 countries

  Non Replicating Viral Vector

• Chinese Academy of Medical Sciences
  Inactivated (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  8 trials in 4 countries

  Inactivated

• Sinopharm (Beijing)
  Covilo

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 93 countries

  39 trials in 18 countries

  Inactivated

• Sinopharm (Wuhan)
  Inactivated (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 2 countries

  9 trials in 7 countries

  Inactivated

• Suzhou Abogen Biosciences
  ABO1009-DP

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  2 trials in 2 countries

  RNA